NasdaqGS:ARWRBiotechs
Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus
Arrowhead Pharmaceuticals (NasdaqGS:ARWR) has been added to the S&P 400 index and its related sector indices.
At the same time, the company has been removed from the S&P 600 index, shifting its classification within the S&P family.
This index change reflects a reclassification of Arrowhead's market standing and may affect how index funds and ETFs hold the stock.
Arrowhead Pharmaceuticals focuses on RNA interference based therapies, an area that has attracted steady attention as drug...